Seres Therapeutics (MCRB) Common Equity: 2015-2025
Historic Common Equity for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $43.7 million.
- Seres Therapeutics' Common Equity rose 82.69% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year increase of 82.69%. This contributed to the annual value of $13.8 million for FY2024, which is 130.73% up from last year.
- Latest data reveals that Seres Therapeutics reported Common Equity of $43.7 million as of Q3 2025, which was up 32.62% from $33.0 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Common Equity peaked at $175.7 million during Q3 2021, and registered a low of -$87.1 million during Q2 2024.
- For the 3-year period, Seres Therapeutics' Common Equity averaged around -$6.1 million, with its median value being $13.8 million (2024).
- Per our database at Business Quant, Seres Therapeutics' Common Equity spiked by 333.10% in 2021 and then slumped by 515.99% in 2023.
- Seres Therapeutics' Common Equity (Quarterly) stood at $131.5 million in 2021, then slumped by 91.80% to $10.8 million in 2022, then crashed by 515.99% to -$44.9 million in 2023, then soared by 130.73% to $13.8 million in 2024, then spiked by 82.69% to $43.7 million in 2025.
- Its Common Equity stands at $43.7 million for Q3 2025, versus $33.0 million for Q2 2025 and $50.5 million for Q1 2025.